FN2 Earnings Intelligence
GE HealthCare Technologies Inc. earnings overview
Latest GE HealthCare Technologies Inc. (GEHC) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
GE HealthCare Technologies Inc.
The quarter supports a constructive operating thesis: resilient orders, backlog and new product adoption point to demand strength, while margin pressure and PCS uncertainty qualify the outlook.
GE HealthCare Technologies Inc.
GE HealthCare entered 2026 with momentum from a record $21.8B backlog and 4.8% organic growth in Q4 2025, but Q1 2026 exposed margin pressure that reshaped the full-year outlook. Revenue of $5.1B grew 2.9% organically and topped consensus by 1.8%, yet EPS of $0.99 fell short of the $1.04 estimate as a pharmaceutical diagnostics supplier recall, rising input costs, and tariff exposure compressed adjusted EBIT margin to 13.5%. Management lowered full-year EPS guidance, completed the Intelerad acquisition to expand cloud and AI imaging, and reorganized into three operating segments. However, the commercial payoff from key new products was pushed to 2027. The stock fell 13.2% on the report before partially recovering 5.7% in subsequent sessions.
GE HealthCare Technologies Inc.
The current analysis supports a constructive but qualified view: record backlog, new high-margin products, recurring service revenue, and enterprise agreements provide growth support, while maintained guidance and ongoing tariff, China, regulatory, and supply risks argue against treating the trajectory as assured.
GE HealthCare Technologies Inc.
GE HealthCare's latest results support a constructive operating picture: demand remained solid, guidance rose, and AI-enabled imaging and radiopharmaceutical products provide growth avenues. The thesis depends on China recovery, Flyrcado execution, tariff mitigation, and conversion of the product pipeline into sustained margin improvement.
GE HealthCare Technologies Inc.
The supplied analysis supports a constructive operating thesis: resilient orders, a record backlog, raised guidance, and progress in nuclear medicine and AI-enabled products indicate continuing demand. The thesis remains conditional on tariff mitigation, China stabilization, margin execution, regulatory progress, and conversion of backlog into revenue.
GE HealthCare Technologies Inc.
The call supports a constructive operating picture through strong orders, backlog, U.S. imaging demand, and product launches, but the lowered guidance shows that tariff costs and execution risks currently temper the case for sustained earnings growth.
GE HealthCare Technologies Inc.
The supplied analysis supports a cautiously constructive operating thesis: broad order growth, record backlog, margin expansion, AI-enabled products, and radiopharmaceutical launches provide growth avenues, but China exposure, tariffs, inventory, and launch execution limit confidence in durability.
Get the GEHC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.